IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations

American Journal of Surgical Pathology

Volumn 37, Issue 3, 2013, Pages 421-426

  Lee, Anna F ^a,b   Gown, Allen M ^b,c   Churg, Andrew ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PHENOPATH LABORATORIES   (United States)

Author keywords

benign mesothelial proliferations; GLUT 1; immunohistochemistry; IMP3; mesothelioma

Indexed keywords

GLUCOSE TRANSPORTER 1; IMP3 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ARTICLE; CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; FIBROMA; HUMAN; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; METABOLISM; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; NEOPLASMS, FIBROUS TISSUE; RNA-BINDING PROTEINS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873993427     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31826ab1c0     Document Type: Article

References (32)

1. Churg A, Cagle PT, Roggli VL. Tumors of the Serosal Membranes. Washington, DC: American Registry of Pathology; 2006.
2. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000; 24:1183-1200.
3. Churg A, Galateau-Salle F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 2012. [In press].
4. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231-238.
5. Cagle PT, Brown RW, Lebovitz RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol. 1994;25:443-448.
6. Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol. 1992;168: 377-381.
7. Ramael M, Lemmens G, Eerdekens C, et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol. 1992;168:371-375.
8. Wolanski KD, Whitaker D, Shilkin KB, et al. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer. 1998;82:583-590.
9. Wu M, Sun Y, Li G, et al. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol. 2007;128:783-787.
10. Wu M, Yuan S, Szporn AH, et al. Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol. 2005;18:1618-1622.
11. Pinheiro C, Longatto-Filho A, Soares TR, et al. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. Diagn Cytopathol. 2012;40:478-483.
12. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215-220.
13. Shi M, Fraire AE, Chu P, et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011;35: 878-882.
14. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49:561-568.
15. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol. 2001;25:43-50.
16. Cury PM, Butcher DN, Fisher C, et al. Value of the mesotheliumassociated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000; 13:107-112.
17. Hanna A, Pang Y, Bedrossian CW, et al. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol. 2010;38:264-269.
18. Nagel H, Hemmerlein B, Ruschenburg I, et al. The value of anticalretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology. Pathol Res Pract. 1998;194:759-764.
19. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14:2729-2733.
20. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene. 2002;287:49-54.
21. Findeis-Hosey JJ, Xu H. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem. 2012;87:24-29.
22. Findeis-Hosey JJ, Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol. 2011;42:303-314.
23. Ikeda K, Tate G, Suzuki T, et al. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol. 2010;41:745-750.
24. Hanley KZ, Facik MS, Bourne PA, et al. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer. 2008;114:49-56.
25. Ikeda K, Tate G, Suzuki T, et al. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol. 2011;39:395-401.
26. Farrell CL, Yang J, Pardridge WM. GLUT-1 glucose transporter is present within apical and basolateral membranes of brain epithelial interfaces and in microvascular endothelia with and without tight junctions. J Histochem Cytochem. 1992;40:193-199.
27. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol. 1996;270:G541-G553.
28. Ito T, Noguchi Y, Satoh S, et al. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol. 1998;11:437-443.
29. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72:2979-2985.
30. Reisser C, Eichhorn K, Herold-Mende C, et al. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer. 1999; 80:194-198.
31. Cantuaria G, Fagotti A, Ferrandina G, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001;92:1144-1150.
32. Lagana SR, Taub RN, Borczuk AC. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med. 2012;136:804-809.